Next-generation sequencing and biomarkers for gastric cancer: what is the future?

Akihito Kawazoe and Kohei Shitara

Abstract: Recent years have witnessed an improved understanding of tumour biology and the molecular features of gastric cancer. Remarkable advances in next-generation sequencing technologies have defined the genomic landscape of gastric cancer. In fact, several molecular classifications have been proposed, and distinct molecular subtypes have been identified, which could serve as a roadmap for patient stratification and trials of targeted therapies. At present, clinical trials of new agents, such as receptor tyrosine kinases inhibitors, antibody–drug conjugates and IMAB362 (anti-Claudin 18.2), are ongoing. Furthermore, biomarkers of immune checkpoint inhibitors or combination therapy have been ardently investigated. These developments could facilitate precision medicine for gastric cancer in the near future.

Keywords: Claudin 18.2, gastric cancer, immune checkpoint inhibitors, molecular profiles, receptor tyrosine kinases

Introduction

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide.1 Although some chemotherapy (CTx) regimens, including a platinum + fluoropyrimidine combination, trastuzumab [for human epidermal growth factor receptor 2 (HER2)-positive cases], taxanes, irinotecan and ramucirumab, reportedly enhance the survival outcomes of patients with advanced GC (AGC),2–6 the prognosis remains poor (median survival ~1 year). Although the phase III ATTRACTION-2 trial of anti-programmed death 1 (anti-PD-1) antibody, nivolumab, reported a survival benefit in AGC,7 the overall response rate (ORR) was approximately 10% and half of the patients exhibited early disease progression. Thus, the establishment of a better selection of patients who might derive greater benefit from PD-1 blockade is warranted. In addition, trifluridine/tipiracil (TAS-102) demonstrated a survival benefit compared with placebo in heavily pretreated patients with AGC.8 However, until recently, several phase III trials of targeting agents for AGC failed to demonstrate a survival benefit (Table 1). Notably, single-agent activity for AGC is minimal, and a few trials have attempted to identify possible biomarkers before phase III trials; thus, better patient stratification based on molecular profiles is crucial.

This study aims to review the molecular features, promising treatment targets and biomarkers of immune checkpoint inhibitors that could facilitate precision medicine for GC in the near future.

Molecular profiles of GC

The molecular characterization of GC has been rapidly evolving recently. To date, several molecular classifications have been proposed, and distinct molecular subtypes have been identified.9–14 Reportedly, several receptor tyrosine kinases (RTKs), such as HER2, epidermal growth factor receptor 1 (EGFR), mesenchymal–epithelial transition factor (MET) and fibroblast growth factor receptor 2 (FGFR2), are amplified in GC, and targeted therapies including these molecules have been developed.15–18 Notably, these amplifications are frequently but not universally mutually exclusive.15–18 In 2014, The Cancer Genome Atlas (TCGA) network characterized 295 gastric adenocarcinoma cases based on six molecular platforms9: somatic copy number analysis, whole-exome sequencing, DNA methylation profiling, messenger RNA sequencing, microRNA sequencing and...
### Table 1. Recent phase III trials of new agents for gastric cancer.

| Target | Trial/authors | Line  | Screening | Agent | control | Endpoint | Results | Difference mOS (m) [HR] |
|--------|---------------|-------|-----------|-------|---------|----------|---------|------------------------|
| HER2   | ToGA          | 1st   | HER2      | Trastuzumab (+ chemo) | OS      | Positive | +2.7 (HR 0.74)        |
| HER2   | Logic         | 1st   | HER2 [FISH] | Lapatinib | PBO (+ chemo) | OS      | Negative | +1.7 (HR 0.91)        |
| HER2   | JACOB         | 1st   | HER2      | Pertuzumab (+ chemo + Tmab) | OS      | Negative | +3.3 (HR 0.84)        |
| HER2   | TyTAN         | 2nd   | HER2 [FISH] | Lapatinib (+ chemo) | OS      | Negative | +3 (HR 0.84)          |
| HER2   | GATSBY        | 2nd   | HER2      | T-DM1 Taxanes | OS      | Negative | ~0.7 (HR 1.15)        |
| EGFR   | REAL-3        | 1st   | –         | Panitumumab (+ chemo) | OS      | Negative | ~2.5 (HR 1.37)        |
| EGFR   | EXPAND        | 1st   | –         | Cetuximab | PBO (+ chemo) | PFS     | Negative | ~1.3 (HR 1.0)         |
| EGFR   | ENRICH        | 2nd   | EGFR [IHC] | Nimotuzumab (+ chemo) | OS      | Terminated |             |
| mTOR   | GRANITE-1     | 2nd/3rd | –         | Everolimus | PBO      | OS      | Negative | +1.05 (HR 0.9)        |
| mTOR   | GRANITE-2     | 2nd   | –         | Everolimus | PBO (+ chemo) | OS      | Negative | +1.0 (HR 0.92)        |
| HGF    | RILOMET1      | 1st   | MET [IHC] | Rilotumumab | PBO (+ chemo) | OS      | Negative | ~2.9 (HR 1.36)        |
| MET    | METgastric    | 1st   | MET [IHC] | Onartuzumab | PBO (+ chemo) | OS      | Negative | ~0.3 (HR 0.82)        |
| VEGF-A | AVAGAST       | 1st   | –         | Bevacizumab | PBO (+ chemo) | OS      | Negative | +2 (HR 0.87)          |
| VEGFR2 | RAINFALL      | 1st   | –         | Ramucirumab | PBO (+ chemo) | OS      | Negative | +0.4 (HR 0.96)        |
| VEGFR2 | REGARD        | 2nd   | –         | Ramucirumab | PBO      | OS      | Positive  | +1.4 (HR 0.776)       |
| VEGFR2 | RAINBOW       | 2nd   | –         | Ramucirumab | PBO (+ chemo) | OS      | Positive  | +2.2 (HR 0.807)       |
| VEGFR2 | Li et al.     | 3rd   | –         | Apatinib | PBO      | OS      | Positive  | +1.8 (HR 0.71)        |
reverse-phase protein array. In addition, microsatellite instability (MSI) testing and whole-genome sequencing were performed. Then, four subtypes of GC were described as follows: (1) tumours positive for Epstein–Barr virus (EBV); (2) MSI-high (MSI-H) tumours; (3) genomically stable (GS) tumours and (4) tumours with chromosomal instability (CIN; Table 2). EBV-positive tumours exhibit recurrent PIK3CA and ARID1A mutations, extreme DNA hypermethylation and high amplification of JAK2, PD-L1 and PD-L2. MSI-H tumours exhibit elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins. GS tumours are enriched for the diffuse histological variant and mutations of CDH1 and RHOA or CLDN18–ARHGAP fusion. CIN tumours are frequently observed at the gastroesophageal junction/cardia with recurrent TP53 mutation and relatively numerous amplifications of RTKs genes. In 2015, The Asian Cancer Research Group (ACRG) proposed four molecular subtypes, including (1) MSI-H, (2) microsatellite stable (MSS) with epithelial–mesenchymal transition features (MSS/EMT), (3) MSS/TP53 mutant (MSS/TP53) and (4) MSS/TP53 wild-type (MSS/TP53; Table 2).10 In the MSS/EMT subtype, nearly 70% of recurrences were at the peritoneum, with a markedly poorer prognosis compared with other subtypes, highlighting the need for therapy development for peritoneal dissemination.10 Recently, Liu et al. reported that gastrointestinal tract adenocarcinomas comprised five molecular subtypes, EBV, MSI, hypermutated single-nucleotide variant predominant (HM-SNV), CIN and GS, to distinguish genomic or immunological features.19 HM-SNV tumours harboured a lower level of CD8 or interferon (IFN)-γ signatures than that of MSI tumours, indicating that indel mutations, which MSI-H tumours often yield, better neoantigens than SNVs. The future clinical trials of targeted and immune therapy in AGC should be designed per differences in genomic or immunological features, as they could affect treatment response and clinical outcomes. Notably, these molecular profiles have been investigated in Japanese AGC. According to GI-SCREEN as the Nationwide Cancer Genome Screening Project, the frequently detected mutations were TP53 (47.8%), PIK3CA (9.2%), KRAS (6.0%), SMAD4 (5.1%), APC (4.1%), TET2 (3.9%), ERBB2 (3.3%) and copy number variants were ERBB2 (11.3%), CCNE1 (11.1%), KRAS (3.7%), FGFR2 (3.3%), ZNF217 (3.3%), MYC (2.7%), CCND1 (2.3%) and CDK6 (2.1%).20 In stage IV AGC, mismatch repair (MMR)-deficient
Table 2. The new molecular-based classification of GC according to The Cancer Genome Atlas (TCGA) 2014 and The Asian Cancer Research Group (ACRG) 2015.

| TCGA                              | Epstein–Barr virus-infected (EBV) | Microsatellite instability (MSI) | Genomically stable (GS) | Chromosomal instability (CIN) |
|-----------------------------------|-----------------------------------|---------------------------------|-------------------------|-----------------------------|
| EBV-positive                      | -                                 | -                               | -                       | Marked aneuploidy            |
| Profound hypermethylation         | -                                 | -                               | -                       | TP53 mutations              |
| CDKN2A silencing                  | -                                 | -                               | -                       | Recurrent amplifications of receptor tyrosine kinases (HER2, 24%) |
| 80% PIK3CA mutation               | -                                 | -                               | -                       | Majority of tumours at the esophagogastric junction |
| PD-L1/2 overexpression            | -                                 | -                               | -                       |                             |
| Immune cell signalling            | -                                 | -                               | -                       |                             |
| Frequent ARID1A and BCOR mutations| -                                 | -                               | -                       |                             |
| Fundus and body                   | -                                 | -                               | -                       |                             |
| Tumours lacking aneuploidy and elevated rates of mutation or hypermethylation | - | - | - | |
| Elevated somatic mutations (PIK3CA, 42%; ERBB3, 26%) | - | - | - | |
| Older patients                    | -                                 | -                               | -                       |                             |
| Tumours lacking aneuploidy and elevated rates of mutation or hypermethylation | - | - | - | |
| Somatic RHOA and CDH1 mutations   | -                                 | -                               | -                       |                             |
| CLDN18–ARHGAP6 or ARHGAP26 fusions| -                                 | -                               | -                       |                             |
| Mostly diffuse subtype            | -                                 | -                               | -                       |                             |
| Marked aneuploidy                 | -                                 | -                               | -                       |                             |
| TP53 mutations                    | -                                 | -                               | -                       |                             |
| Recurrent amplifications of receptor tyrosine kinases (HER2, 24%) | - | - | - | |
| Majority of tumours at the esophagogastric junction | - | - | - | |

| ACRG                              | MSS/TP53-                         | MSI                             | MSS/EMT                  | MSS/TP53                   |
|-----------------------------------|-----------------------------------|---------------------------------|--------------------------|----------------------------|
| Intact TP53                       | -                                 | -                               | -                        | -                          |
| MDM2 amplification               | -                                 | -                               | -                        | -                          |
| EBV infection                     | -                                 | -                               | -                        | -                          |
| Enrichment with PIK3A or ARID1A   | -                                 | -                               | -                        | -                          |
| mutation and cytokine signature in EBV-positive tumours | - | - | - | |
| Hypermutation                     | -                                 | -                               | -                        | -                          |
| Silencing of MLH1                 | -                                 | -                               | -                        | -                          |
| Frequent mutations in KRAS, MTOR, PIK3CA, ASL and ARID1A | - | - | - | |
| Best prognosis                    | -                                 | -                               | -                        | -                          |
| CDH1 silencing                    | -                                 | -                               | -                        | -                          |
| Younger patients                  | -                                 | -                               | -                        | -                          |
| Worst prognosis                   | -                                 | -                               | -                        | -                          |
| TP53 mutation                     | -                                 | -                               | -                        | -                          |
| Genomic instability               | -                                 | -                               | -                        | -                          |
| Recurrent amplification (ERBB2, EGFR, GATA6, MYC, CCNE1 and CCND1) | - | - | - | |
Several recent studies have demonstrated the potential utility of tissue-based NGS and ctDNA NGS for biomarkers of HER2-targeted therapy. Kim et al. reported that CCNE1 amplification and low-level HER2 amplification detected by NGS correlated with the lack of response. The ctDNA analysis revealed that detectable ERBB2 copy number amplification in the plasma was predictive to the response, and changes in plasma-detected genomic alterations correlated with the sensitivity and/or resistance of HER2-targeted therapy. In addition, serial ctDNA sequencing illustrated emergences of other genomic aberrations, such as MYC, EGFR, FGFR2, and MET amplifications, at disease progression. Sanchez-Vega et al. demonstrated that resistance to the pan-HER inhibitor afatinib correlated with the selection of tumour cells with the loss of EGFR amplification or acquired MET amplification, which might be detected in the plasma ctDNA, in a phase II trial of trastuzumab-refractory HER2-amplified AGC. A phase II trial of margetuximab, an anti-HER2 monoclonal Fc-optimised antibody for antibody-dependent cellular cytotoxicity (ADCC), in combination with pembrolizumab demonstrated that ERBB2 amplification detected by ctDNA progressing on trastuzumab could facilitate identifying AGC patients more likely to respond to the study treatment, especially among PD-L1 positive patients. Furthermore, ctDNA NGS could overcome tissue biopsy errors associated with intratumoural heterogeneity, especially at post-treatment progression.

(MMR-D) and EBV tumours are identified in 6.2% and 6.2% cases, respectively. These profiles do not largely differ from prior reports mainly conducted outside Japan, supporting the global development of new agents for AGC. Recently, multiplex gene panels, such as NCC Oncopanel and FoundationOne CDx, were approved in Japan to advance personalized medicine, resulting in further genomic profiling in a large cohort of Japanese patients with AGC. Furthermore, the MSI status could be detected by targeted next-generation sequencing (NGS).

Meanwhile, heterogeneity of genomic alterations is one of the main issues in GC, which could account for some differences in the incidence of mutations or amplifications and inconsistent molecular characterization across various reports. In addition, discordance of dominant oncogenic alterations between primary and metastatic tumour is one of the main issues in GC, which could account for some differences in the incidence of mutations or amplifications and inconsistent molecular characterization across various reports. In contrast, 87.5% concordance for targetable alterations was noted in metastatic tissue and circulating tumour DNA (ctDNA). Furthermore, other studies suggested the dynamic landscape of the ctDNA profile before and after molecular-targeting agents. These analyses should also be incorporated into clinical trials of new agents for AGC to elucidate better treatment biomarkers.

**Promising treatment targets**

**Targeting HER2**

Approximately 60% of patients with GC belong to the CIN subtype and could depend on RTKs signalling for growth and development. HER2 is a therapeutically relevant RTK in 10–20% of the overall GC population and up to 30% of gastroesophageal junction adenocarcinoma harbouring HER2 gene amplification or protein overexpression. In the trastuzumab for GC (ToGA) trial, patients treated with trastuzumab (a HER2-directed monoclonal antibody) and CTx exhibited a significant improvement in overall survival (OS; 13.8 versus 11.1 months; HR, 0.74; p = 0.0046). The OS benefit was the highest in the subset of tumours defined as HER2 immunohistochemistry (IHC) 3+ or IHC2+/fluorescence in situ hybridization (FISH) with unprecedented OS of 16 months in the trastuzumab group compared with 11.8 months with CTx alone [hazard ratio (HR) 0.68; 95% confidence interval (CI) 0.5–0.83]; thus, it became a standard of care for this patient population.

Lately, antibody–drug conjugates have emerged as a promising strategy in cancer therapy and combine the capability of monoclonal antibodies to precisely target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. Nevertheless, trastuzumab-emtansine (T-DM1), an antibody–drug conjugate comprising trastuzumab linked to the cytotoxic agent DM1), which illustrates remarkable efficacy in breast cancer, did not prolong the OS in HER2-positive AGC; this could be, in part, attributed to intratumoural heterogeneity in the HER2 expression and amplification compared with breast cancer. Available evidence indicates that most of HER2-positive GCs are heterogeneous with downregulation in HER2 status post-progression on trastuzumab, as well as diverse intratumoural molecular characteristics. Thus, the assessment of the HER-2 status just before molecular-targeted therapy could be crucial for attaining therapeutic success.
Trastuzumab deruxtecan (DS-8201a) is an antibody–drug conjugate comprising a humanized antibody against HER2, a novel enzyme-cleavable linker and a topoisomerase I inhibitor payload. A preclinical study demonstrated that DS-8201a exerted a potent bystander effect because of a highly membrane-permeable payload and was beneficial in treating tumours with HER2 heterogeneity that are unresponsive to T-DM1.40 Indeed, a phase I study of DS-8201a exhibited the antitumour activity in patients with breast cancer and AGC previously treated with T-DM1 or trastuzumab, and in patients with HER2-low tumours.41 In 44 patients with AGC, the overall response rate (ORR), the disease control rate (DCR) and the median PFS were 43.2%, 79.5% and 5.6 months, respectively.42 A phase II study (DESTINY-Gastric01) in Japan and South Korea assessing the safety and efficacy of DS-8201a in patients with HER2-positive AGC resistant or refractory to trastuzumab is ongoing (ClinicalTrials.gov identifier: NCT03329690).

Recently proposed novel anti-HER2 therapy, ZW25, is reportedly effective and well tolerated in patients with various HER2-positive tumours.43 ZW25 is a bispecific antibody that concurrently binds two HER2 epitopes: ECD4, the trastuzumab-binding domain, and ECD2, the pertuzumab-binding domain. Preclinical research indicated that ZW25 exhibits potent antitumour activity at a range of HER2 expression levels and could more effectively silence HER2 signalling than trastuzumab or pertuzumab and stimulates the immune system. A phase I trial reported a response rate of 38% in heavily pretreated HER2-expressing tumours including GC.44 Further assessment in HER2-positive tumours, including AGC, is ongoing.

In a preclinical study, combining anti-PD-1 and anti-HER2 therapy induce T-cell activation and augment ADCC.45 A phase II trial of the addition of trastuzumab + pembrolizumab to the first-line CTx exhibited promising results with ORR of 87% and the median PFS of 11.4 months, which warrants further evaluation in an ongoing phase III trial (KEYNOTE811; ClinicalTrials.gov identifier: NCT03615326).

**Other RTKs**

Up to 60% of GC cases belong to the CIN subtype, which is commonly related to abnormalities on RTKs signalling.9–15 Various molecular targeting drugs for HER2, EGFR, hepatocyte growth factor (HGF), MET and mammalian target of rapamycin (mTOR) have been assessed; however, most did not exhibit a significant benefit in phase III trials partly because of inappropriate patient selection and molecular stratification (Table 1). Although EGFR, MET or FGFR inhibitors have exhibited antitumour activity for patients with homogenous amplification of these RTKs genes, these cases are relatively rare.46–48

Pearson et al. reported that AGC patients with high-level clonal FGFR2 amplification exhibit a high response rate to FGFR-1, 2, 3 tyrosine kinase inhibitor (TKI), AZD4547, whereas those with subclonal or low-level amplification did not respond.49 A randomised phase II trial (SHINE study) of AZD4547 monotherapy versus paclitaxel for the treatment of AGC patients with FGFR2 polysomy or gene amplification reported that AZD4547 did not markedly enhance the median PFS compared with paclitaxel.50 Exploratory biomarker analyses of the SHINE study revealed marked intratumoural heterogeneity of FGFR2 amplification and poor concordance between amplification/polysomy and FGFR2 mRNA expression, indicating that the failure to adequately enrich a clonally amplified population might contribute to the failure of this study.50 Moreover, AGC patients with high-level FGFR2 amplification attained an objective response for TAS-120, a highly selective covalent FGFR inhibitor.51 FPA144, an ADCC-enhanced, FGFR2b isomform-specific monoclonal antibody, exhibited antitumour activity in patients with FGFR2b+ high (IHC 3+ ⩾10% tumour membrane staining) AGC with an ORR of 19% and a DCR of 57%, respectively. A phase III trial assessing FPA144 and mFOLFOX6 in patients with previously untreated AGC is ongoing. Recently, FGFR2–ACSL5 fusion was identified in an AGC patient with acquired resistance to FGFR inhibition in FGFR2-amplified AGC. Furthermore, JHDM1D–BRAF fusion results in resistance for FGFR inhibitor-resistant cell line, which warrants further research.52,53

Although a phase II trial of oral EGFR TKI erlotinib reported an objective response in 4 of 44 patients with gastroesophageal junction adenocarcinoma,54 no apparent correlation was reported between objective response and tumour biomarkers, such as IHC or FISH. To date, several phase III trials of monoclonal antibodies for EGFR had
been conducted; however, no study has reported a survival benefit of phase III trials (Table 1). A subgroup analysis of the EXPAND study, in which adding cetuximab to first-line capecitabine and cisplatin CTx failed to enhance the clinical outcome in patients with AGC, reported a tendency for enhanced OS, PFS and ORR in a small population of patients with high tumour EGFR IHC scores. Furthermore, Maron et al. reported that anti-EGFR treatment attained an objective response in a small population of patients with high-level EGFR amplification detected by both tissue-based NGC and ctDNA NGS.

The addition of HGF and c-MET signalling inhibitors (onartuzumab as anti-MET monoclonal antibody or rilotumumab as anti-HGF monoclonal antibody) to first-line CTx in MET-positive AGC detected by IHC did not exhibit clinical benefit in phase III trials, although MET TKIs have exhibited antitumour activity in some patients with high-level MET amplification. The lack of appropriate patient selection and molecular stratification could be one of the reasons for the failure in these trials. Considering that the amplification of RTKs does not simply correlate with the protein expression in GC, a comprehensive analysis using both NGC and IHC could be necessary to select patients adequately.

**VEGF targeting therapy**

Ramucirumab is a human IgG1 monoclonal antibody specific for vascular endothelial growth factor receptor 2 (VEGFR2), which has recently been validated to be effective for AGC by the REGARD and RAINBOW trials. In the RAINBOW trial, which compared paclitaxel + placebo with paclitaxel + ramucirumab, patients treated with paclitaxel + ramucirumab exhibited significantly longer OS (median, 9.6 versus 7.4 months), longer PFS (median, 4.4 versus 2.9 months) and higher response rate (28% versus 16%) than those treated with paclitaxel alone. Regrettably, an optimal biomarker for antiangiogenic treatment is still lacking. A recent retrospective exploratory analysis from the REGARD study reported that none of the tested biomarkers (tumour HER2 or VEGFR2 and serum VEGF-C and VEGF-D, and soluble VEGFR1 and VEGFR3) identified a potent predictive biomarker of ramucirumab efficacy. Moreover, per the exploratory plasma analyses from the RAINBOW study, neither VEGF pathway markers nor other markers revealed a predictive correlation with ramucirumab efficacy. Recently, the RAINFALL phase III trial demonstrated that adding ramucirumab to first-line cisplatin/fluoropyrimidine did not exhibit enhanced OS, which also failed to exhibit the utility of plasma biomarkers, such as VEGF-C and VEGF-D. A phase III double-blind placebo-controlled study of regorafenib, multiple VEGF TKIs in patients with AGC is underway, which will also assess predictive biomarkers of this antiangiogenic treatment. Furthermore, apatinib is a multikinase inhibitor that primarily targets VEGFR2 and markedly enhances OS in patients with pretreated AGC, although no biomarkers were identified to predict clinical benefits.

**PARP inhibitor**

The GC pathogenesis is associated with DNA damage and chronic inflammation from *Helicobacter pylori* and EBV infections to lifestyle factors including obesity and chronic gastric acid reflux. Large-scale genome sequencing of GC suggested that somatic mutations in genes involved in homologous recombination DNA repair are common features. Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor that blocks DNA base-excision repair and causes synthetic lethality in tumours with homologous recombination repair deficiencies. Ataxia–telangiectasia mutated (ATM) is a gene essential to the cellular double-strand DNA breaks response essential to maintain genome stability levels. In a phase II trial of olaparib combined with paclitaxel versus placebo combined with paclitaxel as second-line therapy, a higher OS benefit was noted in AGC patients with ATM-negative tumours (HR 0.35; p = 0.002). Unfortunately, the phase III GOLD trial did not report improved OS with olaparib in patients with ATM-negative tumours (HR 0.73; p = 0.25) as well as overall population (HR 0.79, p = 0.026), indicating that patient selection by the ATM status was not sufficient. Biomarker analysis of the GOLD study revealed that none of the other genetic markers of DNA damage repair, which have proven predictive in other tumour types for full-dose olaparib monotherapy, correlated with the sensitivity to low-dose olaparib combination with paclitaxel in patients with AGC. A phase III trial comparing PARP inhibitor BGB-920 with placebo as maintenance therapy in patients with AGC who responded to first-line platinum-based CTx is under way, which would also assess
the sensitivity to PARP inhibitor monotherapy from tumour specimen. Based on a preclinical study demonstrating that PARP inhibitor upregulates the PD-L1 expression on tumour cells,69 a phase II trial of olaparib and anti-PD-L1 antibody, durvalumab, was conducted, resulting in an ORR of 10% and a DCR of 25% after 12 weeks because of a high rate of early disease progression following olaparib monotherapy for 4 weeks,70 which will be explored in combination with CTx.

Targeting therapy for stemness-related pathway or cancer stroma

Cancer stem cells (CSCs) exhibit self-renewal capability and could contribute to malignant tumour growth, disease relapse and metastasis. Signal transducer and activator of transcription 3 (STAT3) activation is one of the hallmarks associated with cancer ‘stemness’. STAT3 acts as a transcription factor located downstream of various pro-oncogenic cytokines and JAK. Reportedly, phosphorylated STAT3 activates the transcription of Nanog and Myc genes.71 BBI608 (napabucasin) is an orally administered investigational small molecule presumed to affect multiple oncogenic cellular pathways, including the inhibition of STAT3, which has been implicated in providing CSCs with stemness characteristics.71 Encouraging the antitumour activity of BBI608 and paclitaxel in refractory AGC was observed in a phase Ib and subsequent phase II study with an ORR of 31% and a DCR of 75%.72 Nevertheless, a phase III trial (BRIGHTER) of BBI608 + weekly paclitaxel versus placebo + weekly paclitaxel in patients with AGC failed to improve the OS.73

Reportedly, a subpopulation of gastric carcinoma cells expressing EPCAM, CD44, CD44 variant (CD44v), CD133 and CD166 exhibited the properties to generate new heterogeneous tumours in vitro.74 Sulfasalazine is an inhibitor of the cysteine–glutamate exchange transporter, a variant form of CD44v. Sulfasalazin induces a reduction in CD44v-positive cells and intracellular reduced glutathione levels in patients with AGC.75 However, a phase I trial of the combination of sulfasalazin with cisplatin in patients with CD44v-expressing AGC refractory to cisplatin did not exhibit an apparent antitumour activity.76

Recently, Nanki et al. illustrated divergent genetic and epigenetic routes to gain Wnt and R-spondin niche independency in phenotype analyses of GC organoids, and a marked correlation between CDH1/TP53 compound mutations, which were also identified in the TCGA 2014 report,7 and R-spondin independency (Wnt-dependent GC).77 In this study, xenografting of GC organoids established the feasibility of Wnt-targeting therapy for Wnt-dependent GC.77 Most recently, a preclinical study reported that the Wnt receptor Fzd7 is a promising target for GC irrespective of the APC mutation status.78

Dickkopf-1 (DKK1) is a modulator of the Wnt and PI3K–AKT signalling pathways and contributes to an immunosuppressive tumour microenvironment by activating MDSCs and regulatory T cells (Tregs). DKN-01, a monoclonal antibody against DKK1, acts on innate immune cells, and a preclinical study illustrated the upregulation of both PD-L1 and IFN-γ-related chemokines, indicating a rational for immune checkpoint combination. A phase Ib trial of DKN-01 in combination with pembrolizumab reported encouraging antitumour activity in AGC with an ORR of 23.5% and a DCR of 58.8%, which warrants further investigation.79

MMP-9

Matrix metalloproteinases-9 (MMP-9) is an extracellular enzyme involved in matrix remodelling, angiogenesis, tumour growth and metastasis.80 Chen et al. reported a higher expression of MMP-9 in the GC tissue than that in the adjacent healthy tissues.81 Moreover, its overexpression reportedly correlated with the poor prognosis of GC.82 Preclinical studies demonstrated that MMP-9 inhibition alters the tumour microenvironment, which correlates with higher CTx penetration and enhanced antitumour immunity. Andecaliximab is a monoclonal antibody that inhibits MMP-9 and has been combined with various CTx regimens. A phase I/Ib trial of mFOLFOX6 + andecaliximab revealed encouraging antitumour activity in AGC patients with the median PFS of 9.9 months in the first-line setting and the ORR of 50%.83 However, a subsequent phase III study of andecaliximab combined with mFOLFOX6 in the first-line setting for patients with AGC did not markedly improve the OS.84

Claudin 18.2

Claudin18.2 (CLDN18.2) is a member of the claudin family of >20 structurally related proteins that form vital components of the tight cell
junctions in epithelia and endothelia;\textsuperscript{85} it is not expressed in any healthy tissue, except the stomach mucosa, but broadly expressed in various cancer types including AGC, especially in diffuse-type GCs.\textsuperscript{86} Moreover, CLDN18-ARHGAP26/6 fusions have been identified in GCs, with a predominance in GS-type tumours based on the TCGA classification.\textsuperscript{9} Reportedly, almost all CLDN18–ARHGAP26/6 fusion-positive GCs expressed CLDN18.2 protein with a higher prevalence of lymphatic and distant organ metastases, especially in the younger age patients.\textsuperscript{87} Furthermore, the TCGA data demonstrated that the CLDN18–ARHGAP26/6 fusion was mutually exclusive with driver genes, such as \textit{RHOA} and \textit{CDH1} mutations, which were frequently noted in GS-type tumours.\textsuperscript{9}

IMAB362 (zolbetuximab) is a novel chimeric IgG1 antibody highly specific for CLDN18.2; it binds to CLDN18.2 on the tumour cell surface to stimulate cellular and soluble immune effectors that activate antibody-dependent cytotoxicity and complement-dependent cytotoxicity.\textsuperscript{88} A phase II study (MONO) demonstrated the efficacy and safety of IMAB362 as monotherapy in patients with metastatic, refractory or recurrent GC.\textsuperscript{90} Among 40 patients who received IMAB362 600 mg/m\textsuperscript{2}, the ORR was 10% and the DCR was 30%. A randomized phase II study (FAST) demonstrated that IMAB362 in combination with first-line CTx exhibited clinically relevant benefit in the PFS and OS in patients with CLDN18.2-positive AGC.\textsuperscript{90} IMAB362 + EOX significantly enhanced the PFS (median 7.9 versus 4.8 months; HR 0.47; \( p = 0.0001 \)) and OS (median 13.3 versus 8.4 months; HR 0.51; \( p < 0.001 \)) compared with EOX alone. A subgroup analysis revealed that the CLDN18.2 expression in \( \geq 70\% \) of tumour cells correlated with better OS (HR, 0.44), resulting in further patient enrichment (\( \geq 75\% \) of tumour cells) in an ongoing phase III study (Spotlight), which assesses the efficacy of IMAB362 + mFOLFOX6 compared with placebo + mFOLFOX6 as first-line CTx. Reportedly, high claudin18.2 expression (\( \geq 75\% \) of tumour cells) was detected in 36% of patients with AGC.\textsuperscript{90}

Recently, a preclinical study indicated that partial or complete tumour elimination was observed in CLDN18.2-positive GC patient-derived tumour xenograft models treated with CLDN18.2-specific CAR T cells.\textsuperscript{91} A first-in-class CAR-Claudin18.2 T cell trial for the treatment of gastric and pancreatic cancer is ongoing. Overall, CLDN18.2 is a promising novel treatment target for IMAB362 combined with first-line CTx and CLDN18.2-specific CAR T cells in patients with AGC.

**Immune checkpoint inhibitors and its biomarkers**

Recently, blockade of immune checkpoint molecules with monoclonal antibodies has emerged as a promising strategy in several malignancies.\textsuperscript{92–97} PD-1, which belongs to the CD28 family of proteins, is a negative costimulatory receptor expressed on the surface of activated T cells.\textsuperscript{98} The binding of PD-1 and its ligands, PD-L1 and PD-L2 in tumour or immune cells, can inhibit a cytotoxic T-cell response, which leads tumour cells to escape from immune surveillance.\textsuperscript{98} Accordingly, the blockade of this interaction restores the antitumour activity of T cells.\textsuperscript{98} Clinical trials of anti-PD-1/PD-L1 monoclonal antibodies have reported durable antitumour response and enhanced OS in several malignancies.\textsuperscript{92–97}

A phase III ATTRACTIION-2 trial of nivolumab, a fully human IgG4 monoclonal antibody against PD-1, for patients with AGC after two or more previous line CTxs demonstrated a survival benefit, resulting in the approval of nivolumab for AGC in Japan as third-line or later-line treatment.\textsuperscript{7} However, subsequent randomized trial of anti-PD1/PD-L1 in earlier trials failed to exhibit a survival benefit compared with standard CTx; thus, better treatment selection is warranted to use anti-PD1/PD1 in earlier treatment lines.

**PD-L1 expression**

An exploratory analysis of ATTRACTION-2 indicated no predictive value of PD-L1 expression on tumour cells.\textsuperscript{7} Moreover, in JAVELIN 300, which recently failed to establish a survival benefit for avelumab compared with the investigators’ choice of CTx with paclitaxel or irinotecan for patients with AGC, no difference was observed in the OS based on the PD-L1 expression, which was defined as PD-L1 staining on 1% of tumour cells.\textsuperscript{99} Results remained the same when PD-L1 was also assessed on immune cells, although the methodology for this assessment is not described. However, a correlation between higher PD-L1 expression (using the combined positive score (CPS), which is a proportional assessment of
PD-L1 staining on both tumour and immune cells, and higher treatment effect was suggested in phase II (KEYNOTE-059) and III trials (KEYNOTE-061) of pembrolizumab. In KEYNOTE-059, the ORR in the third-line setting was 22.7% for patients with PD-L1 expression (CPS ≥1) as determined by 22C3 IHC assay, whereas the ORR was 8.6% for those with PD-L1-negative tumours, resulting in US Food and Drug Administration (FDA) approval of pembrolizumab for PD-L1-positive AGC and PD-L1 22C3 IHC as a companion diagnostic assay. Although KEYNOTE-061 failed to demonstrate improvement in the OS with pembrolizumab in CPS ≥1 population, patients who expressed high levels of PD-L1 (CPS ≥10) exhibited a pronounced benefit from treatment with pembrolizumab in CPS ≥1 population, patients who expressed high levels of PD-L1 (CPS ≥10) exhibited a pronounced benefit from treatment with pembrolizumab (HR 0.64; 95% CI 0.41–1.02). The ORRs of pembrolizumab in patients with CPS ≥10, CPS ≥1 and CPS <1 (PD-L1-negative) were 25%, 16% and 2%, respectively. The impact of CPS on the efficacy of PD-1 blockade will also be assessed in the ongoing phase III trial (KEYNOTE-062), which compared the efficacy of cytotoxic agents combined with pembrolizumab in patients with PD-L1-positive or PD-L1-negative responses. Other combinations therapy might be necessary to enhance outcomes in PD-L1 negative patients.

**Other factors to predict response**

As patients with MSI-H/MMR-D form a small minority of AGC patients, novel biomarkers to predict response to immunotherapy among MSS/MMR-P are desired. A recent study reported that tumour mutation burden (TMB) correlated with enhanced survival in patients receiving immune checkpoint inhibitors across multiple cancer types. Moreover, Kim et al. reported that TMB was a potential biomarker of pembrolizumab for AGC. However, most patients with high TMB had MSI-H/MMR-D status, and not all patients with high TMB attained an objective response. Hence, the precise mechanism regarding the impact of TMB on the efficacy of PD-1/PD-L1 blockade should be investigated in the near future. The TCGA reported that the amplification of the CD274 gene (which encodes PD-L1) and the PDCD1LG2 gene (which encodes PD-L2) was frequently observed in EBV-positive GC. Indeed, AGC patients with EBV-positive status reported higher benefit from pembrolizumab. Notably, Panda et al. reported that a patient with EBV-positive AGC exhibited durable response from treatment with the anti-PD-L1 antibody avelumab, although this tumour had low mutation.

**MSI-H**

As shown in the TCGA 2014 and ACRG 2015 reports, the MSI-H subtype exhibits frequent mutations in multiple genes (including frameshifts or missense mutations) and hypermethylation (including hypermethylation at the MLH1 promoter), which contribute to the enhanced expression of neoantigens. MSI-H/MMR-D colorectal cancer has higher mutation loads than that of MSS/MMR-proficient (MMR-P) colorectal cancer, resulting in high infiltration of CD8+ T cells presumably because of the recognition of a high number of tumour neoantigens and its corresponding expression of immune checkpoints in the tumour microenvironment. Indeed, the FDA approved pembrolizumab for patients with MSI-H or MMR-D solid tumours, including AGC based on the durable response in several trials.
A study recently reported that the ORR of nivolumab for AGC after two or more CTx regimens was significantly higher in patients with MMR-D than in those with MMR-P (75% versus 13%), PD-L1+ in tumour cells than in those with PD-L1- in tumour cells (57% versus 13%) and PIK3CA mutation in those with PIK3CA wild-type (44% versus 14%).110 Remarkably, the ORR was 31% in patients with at least, one of the following factors: MMR-D, high-TMB, EBV-positive and PD-L1+ in tumour cells versus 0% in those without these factors, suggesting that pre-screening of these biomarkers could be useful in predicting the clinical benefit of the anti-PD-1/ PD-L1 blockade in AGC. Moreover, the diversity and composition of gut microbiome reportedly predicts the effect of PD-1 blockade in patients with AGC.111 A recent subgroup analysis of ATTRACTION-2 indicated that patients with hyponatraemia along with high neutrophil-to-lymphocyte ratio might exhibit low benefit with nivolumab in terms of early progression and death.112

**Controversy in hyperprogressive disease**

Recently, anti-PD-1/PD-L1 antibodies have anecdotally been reported to cause rapid progression of some cancer types, which is called hyperprogressive disease (HPD),113–116 although its exact incidence in GC remains unclear. As HPD, perhaps, correlates with poor prognoses, it is imperative to identify predictive factors of HPD. Kato et al. identified EGFR mutations and MDM2 amplification as possible molecular predictors of HPD in patients with several solid tumours.115 Reportedly, FBXW7 mutation or KRAS amplification could be related to HPD in patients with AGC who received nivolumab.117 Recently, Togashi et al. reported an increase in Tregs with proliferative capacity among tumour-infiltrating lymphocytes in AGC patients who exhibited HPD after treatment with an anti-PD-1 antibody.118 Moreover, an in vitro study reported that PD-1 blockade activated not only effector T cells but also Tregs, which promoted tumour progression in a fraction of patients.118 Further investigations in larger cohorts are warranted to validate HPD-associated biomarkers. Recently, Lo Russo et al. illustrated the role of innate immunity in mediating hyperprogression via Fc/FcR triggering on macrophages by anti-PD-1 antibody.119 A previous in vivo study reported that selective inhibition of the VEGF pathway with an anti-VEGF antibody or anti-VEGF TKIs effectively controlled tumour growth and inhibited the infiltration of suppressive immune cells such as Tregs and tumour-associated macrophages, myeloid-derived suppressor cells, while increasing the mature dendritic cell fraction.120 In addition, heat shock protein 90 (HSP90) inhibitor reportedly enhance antitumour immunity by decreasing Tregs in vitro and in vivo. Based on these preclinical rational, clinical trials of anti-PD1 antibodies in combination with multiple VEGF TKIs or HSP90 inhibitor are under way, which might not only enhance antitumour activity but also reduce HPD.

**Conclusions**

Remarkable advances in elucidating molecular profiles of GC have facilitated the development of novel agents such as RTKs inhibitors, antibody–drug conjugates and IMAB362 (anti-Claudin 18.2). In addition, developing appropriate biomarkers for patient selection in early clinical trials could lead to successful results of pivotal clinical trials of new drugs. Considering that the apparent efficacy of PD-1 blockade might be limited to a relatively small subset of AGC patients and some patients exhibit HPD, better biomarkers of immune checkpoint inhibitors or combination therapy should be established in the near future.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest statement**

KS reports providing a consulting or advisory role for Astellas, Bristol-Myers Squibb, Lilly, Ono, Pfizer and Takeda; receiving personal fees from AbbVie, Novartis and Yakult and research funding from Chugai, Daiichi Sankyo, Lilly, MSD, Ono, Sumitomo Dainippon and Taiho. AK reports receiving research funding from Ono, Sumitomo Dainippon and Taiho. AK reports receiving research funding from Ono, Sumitomo Dainippon and Taiho. AK reports receiving research funding from Ono, Sumitomo Dainippon and Taiho.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in
Microsatellite instability is associated with the microsatellite instability-high (MSI-high) phenotype. It is characterized by the accumulation of errors in DNA replication due to defects in DNA mismatch repair (MMR) genes. This phenotype is associated with specific tumor types, including colorectal, endometrial, and gastric cancers. In gastric cancer, MSI-high tumors are rare but have distinct clinicopathological features and clinical outcomes.


gastrointestinal adenocarcinomas. Cancer Cell 2018; 33: 721–735.
21. Yuki S, Shirata K, Kadowaki S, et al. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: efficient identification of cancer genome alterations in advanced gastric cancer (GC). J Clin Oncol 2018; 36: abstract 4050.
22. Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the
presence of Lynch syndrome pan-cancer. *J Clin Oncol* 2019; 37: 286–295.

23. Stahl P, Seeschaf C, Lebok P, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. *BMC Gastroenterol* 2015; 15: 7.

24. Pectasides E, Stachler MD, Derks S, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. *Cancer Discov* 2018; 8: 37–48.

25. Kim ST, Banks KC, Pectasides E, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. *Ann Oncol* 2018; 29: 1037–1048.

26. Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. *Clin Cancer Res* 2018; 24: 6248–6256.

27. Riches JC, Schultz N, Ku Gy, et al. Genomic profiling of esophagogastric (EG) tumors in clinical practice. *J Clin Oncol* 2015; 33(Suppl. 3): abstract 57.

28. Secrrier M, Li X, de Silva N, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. *Nat Genet* 2016; 48: 1131–1141.

29. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; 376: 687–697.

30. Kim ST, Banks KC, Pectasides E, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. *Ann Oncol* 2018; 29: 1037–1048.

31. Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. *Cancer Discov* 2018; 8: 49–58.

32. Lee JY, Hong M, Kim ST, et al. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. *Sci Rep* 2018; 9: 199–209.

33. Catenacci DV, Park H, Uronis HE, et al. Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma. *Ann Oncol* 2018; 29(Suppl. 8): viii205–viii270.

34. Kang YK, Shah MA, Ohtsu A, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/ gastroesophageal junction adenocarcinoma (LA/ MGC/GEJC). *J Clin Oncol* 2016; 34(Suppl. 4S): abstract 5.

35. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. *Mod Pathol* 2012; 25: 637–650.

36. Lee JY, Horn M, Kim ST, et al. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. *Sci Rep* 2015; 5: 9289.

37. Press MF, Ellis CE, Gagnon RC, et al. HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/ LOGiC trial of lapatinib. *Mol Cancer Ther* 2017; 16: 228–238.

38. Jänigian Y, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. *Cancer Discov* 2018; 8: 49–58.

39. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. *Clin Cancer Res* 2016; 22: 5097–5108.

40. Doi T, Shiitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. *Lancet Oncol* 2017; 18: 1512–1522.

41. Shiitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. *Lancet Oncol* 2017; 18: 1512–1522.

42. Funda MB, Murali B, Jose L, et al. Single agent activity of ZW25, a HER2-targeted...
bi-specific antibody, in heavily pretreated HER2-expressing cancers. J Clin Oncol 2018; 36: abstract 2500.

44. Beermann M, Hamilton E, Hanna D, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in HER2-expressing gastrointestinal and other cancers. Molecular Targets and Cancer Therapeutics (ENA2018). Paper presented at the 30th EORTC-NCI-AACR Symposium, 13–16 November 2018, Dublin.

45. Janjigian YY, Chou JF, Simmons M, et al. First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). J Clin Oncol 2019; 37(Suppl. 4): abstract 62.

46. Kwak EL, LoRusso P, Hamid O, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastrointestinal junction (GEJ), gastric (G), or esophageal (E) cancer [abstract]. J Clin Oncol 2015; 33(Suppl. 3): abstract 1.

47. Shitara K, Kim TM, Yokota T, et al. Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. Oncotarget 2017; 8: 79546–79555.

48. Smyth EC, Turner NC, Peckett C, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J Clin Oncol 2015; 33: abstract 2508.

49. Pearson A, Smyth EC, Babina IS, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 2016; 6: 838–851.

50. Van Cutsem E, Bang YJ, Mansoor W, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol 2017; 28: 1316–1324.

51. Kuboki Y, Matsumura N, Bando H, et al. First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. Ann Oncol 2017; 28(Suppl. 5): v122–v141.

52. Sase H, Nakanishi Y, Aida S, et al. Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2-amplified gastric cancer. Mol Cancer Ther 2018; 17: 2217–2225.

53. Kim SY, Ahn T, Bang H, et al. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget 2017; 8: 15014–15022.

54. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922–4927.

55. Lordick F, Kang YK, Salman P, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol 2013; 31: abstract 4021.

56. Maron SB, Alpert L, Kwak HA, et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov 2018; 8: 696–713.

57. Shah MA, Bang YJ, Lordick F, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol 2017; 3: 620–627.

58. Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastroesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1467–1482.

59. Fuchs CS, Tabemero J, Tomasek J, et al. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer 2016; 115: 974–982.

60. Van Cutsem E, Muro K, Cunningham D, et al. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 696–713.

61. Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFAIR): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 420–435.

62. Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase
III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. *J Clin Oncol* 2016; 34: 1448–1454.

63. Marshall BJ and Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; 1: 1311–1314.

64. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; 345: 784–789.

65. Kusano M, Toyota M, Suzuki H, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein–Barr virus. *Cancer* 2006; 106: 1467–1479.

66. Bang YJ, Im SA, Lee KW, et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. *J Clin Oncol* 2015; 33: 3858–3865.

67. Bang YJ, Xu RH, Chin K, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017; 18: 1637–1651.

68. Liu Y, Hodgson D, Locker G, et al. Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer. *Ann Oncol* 2018; 29(Suppl. 8): viii14–viii57.

69. Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. *Clin Cancer Res* 2017; 23: 3711–3720.

70. Bang YJ, Kaufman B, Geva R, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed gastric cancer. *J Clin Oncol* 2019; 37: abstract 140.

71. Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. *Proc Natl Acad Sci USA* 2015; 112: 1839–1844.

72. Becerra C, Stephenson J, Jonker DJ, et al. Phase Ib/II study of cancer stem cell (CSC) inhibitor BBi608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. *J Clin Oncol* 2015; 33: abstract 4069.

73. Shah MA, Muro K, Shitara K, et al. The BRIGHTER trial: A phase III randomized double-blind study of BBi608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma. *J Clin Oncol* 2017; 33: abstract 4010.

74. Nguyen PH, Giraud J, Chambonnier L, et al. Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma. *Clin Cancer Res* 2017; 23: 1586–1597.

75. Shitara K, Doi T, Nagano O, et al. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). *Gastric Cancer* 2017; 20: 341–349.

76. Shitara K, Doi T, Nagano O, et al. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). *Gastric Cancer* 2017; 20: 1004–1009.

77. Nanki K, Toshimitsu K, Takano A, et al. Divergent routes toward Wnt and R-spondin niche independence during human gastric carcinogenesis. *Cell* 2018; 174: 856–869.

78. Flanagan DJ, Barker N, Costanzo NSD, et al. Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. *Cancer Res* 2019; 79: 970–981.

79. Klempner SJ, Bendell J, Meucci Villafior V, et al. Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies. *Ann Oncol* 2018; 29: mdy282–044.

80. Coussens LM, Fingleton B and Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science* 2002; 295: 2387–2392.

81. Chen SZ, Yao HQ, Zhu SZ, et al. Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. *Oncol Lett* 2015; 9: 915–919.

82. Zhang QW, Liu L, Chen R, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. *Asian Pac J Cancer Prev* 2012; 13: 2903–2908.

83. Shah MA, Starodub A, Sharma S, et al. Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma:
results from a phase I study. *Clin Cancer Res* 2018; 24: 3829–3837.

84. Shah MA, Ruiz EY, Bodoky G, et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). *J Clin Oncol* 2019; 37(Suppl. 4): abstract 4.

85. Niimi T, Nagashima K, Ward JM, et al. Claudin-18, a novel downstream target gene for the T/EBP/NKK2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. *Mol Cell Biol* 2001; 21: 7380–7390.

86. Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. *Clin Cancer Res* 2008; 14: 7624–7634.

87. Tanaka A, Ishikawa A, Ushiku T, et al. Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset. *Oncotarget* 2018; 9: 29336–29350.

88. Singh P, Toom S and Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for highly metastatic diffuse-type gastric cancer. *J Hematol Oncol* 2017; 10: 105.

89. Trarbach T, Schuler M, Zvirbule Z, et al. Efficacy and safety of multiple doses of IMAB362 in patients with advanced gastroesophageal cancer: results of a phase II study. *Ann Oncol* 2014; 25(4 Suppl.): iv218.

90. Al-Batran SE, Schuler MH, Zvirbule Z, et al. FAST: an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. *J Clin Oncol* 2016; 34: LBA4001.

91. Jiang H, Shi Z, Wang P, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. *J Natl Cancer Inst*. Epub ahead of print 2018. DOI: 10.1093/jnci/djy134.

92. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012; 366: 2443–2454.

93. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015; 372: 320–330.

94. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 2016; 375: 1823–1833.

95. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016; 387: 1540–1550.

96. Charles SF, Doi T, Raymond WJJ, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. *J Clin Oncol* 2017; 35: abstract 4003.

97. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015; 373: 1803–1813.

98. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012; 12: 252–264.

99. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. *Ann Oncol* 2018; 29: 2052–2060.

100. Shitara K, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2018; 392: 123–133.

101. Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. *J Clin Oncol* 2018; 36: 2836–2844.

102. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite unstable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov* 2015; 5: 43–51.

103. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015; 372: 2509–2520.
104. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017; 357: 409–413.

105. Diaz LA Jr, Marabelle A, Delord JP, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. *J Clin Oncol* 2017; 35: abstract 3071.

106. Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol* 2019; 30: 19–33.

107. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* 2019; 51: 202–206.

108. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* 2018; 24: 1449–1458.

109. Panda A, Mehnert JM, Hirshfield KM, et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. *J Natl Cancer Inst* 2018; 110: 316–320.

110. Mishima S, Kawazoe A, Nakamura N, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. *J Immunother Cancer* 2019; 7: 24.

111. Fukuoka S, Motooka D, Togashi Y, et al. Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies. *J Clin Oncol* 2018; 36: 3011.

112. Kang YK, Satoh T and Chao Y. Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2. *J Clin Oncol* 2019; 37(Suppl. 4): abstract 8.

113. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. *Clin Cancer Res* 2017; 23: 1920–1928.

114. Saada-Bouzid E, Defaucheux C, Karabajkian A, et al. Hyperprogression during anti-PD-1/ PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol* 2017; 28: 1605–1611.

115. Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. *Clin Cancer Res* 2017; 23: 4242–4250.

116. Kurman JS and Murgu SD. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. *J Thorac Dis* 2018; 10: 1124–1128.

117. Sasaki A, Nakamura Y, Mishima S, et al. Predictive factors for hyperprogression during nivolumab treatment in patients with advanced gastric cancer. *Gastric Cancer*. Epub ahead of print 2018. DOI: 10.1007/s10120-018-00922-8.

118. Togashi Y, Kamada T, Sasaki A, et al. Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients. *J Clin Oncol* 2018; 36: abstract 4106.

119. Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/ PD-L1 blockade. *Clin Cancer Res* 2019; 25: 989–999.

120. Roland CL, Lynn KD, Toombs JE, et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. *PLoS One* 2009; 4: e7669.